- Condition: Heart Failure
Intervention: Drug: CLP
Sponsors: Sorbent Therapeutics; Sorbent Therapeutics
Recruiting - verified May 2012 - Condition: Duchenne Muscular Dystrophy
Interventions: Drug: eplerenone; Drug: placebo
Sponsors: Ohio State University; Subha Raman; Ballou Skies
Recruiting - verified May 2012 - Condition: Type 2 Diabetic Nephropathy
Interventions: Drug: PF-03882845; Drug: PF-03882845; Drug: PF-03882845; Drug: Spironolactone; Other: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Pulmonary Hypertension
Interventions: Drug: Spironolactone; Drug: Placebo
Sponsors: Baylor College of Medicine; Baylor College of Medicine; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011 - Condition: Heart Failure
Interventions: Device: HM II (HeartMate II LVAD); Drug: OMM (Optimal Medical Management)
Sponsors: Thoratec Corporation; Thoratec Corporation
Recruiting - verified March 2012 - Conditions: Obesity; Hyperandrogenemia; Polycystic Ovary Syndrome
Interventions: Drug: Spironolactone; Drug: Dexamethasone; Drug: Cosyntropin; Drug: r-hCG (Ovidrel)
Sponsors: University of Virginia; University of Virginia
Not yet recruiting - verified August 2011 - Condition: HIV
Interventions: Drug: Eplerenone and lifestyle; Other: placebo and lifestyle
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified February 2012 - Conditions: Obesity; Insulin Resistance
Interventions: Drug: Spironolactone; Drug: Placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital
Recruiting - verified May 2012 - Conditions: Hypertension; Metabolic Syndrome
Intervention: Drug: Aliskerin/Valsartan and Rampiril
Sponsors: University of Michigan Health System; University of Michigan Health System; Novartis Pharmaceuticals
Recruiting - verified September 2011 - Condition: Hypoglycemia
Intervention: Drug: Eplerenone
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Robert Wood Johnson Foundation
Recruiting - verified July 2011 - Condition: Polycystic Ovary Syndrome
Intervention: Drug: folate-boosted 3 mg DRSP/20 μg EE-24/4 oral contraceptive
Sponsors: BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Recruiting - verified March 2012 - Condition: Hypertension
Interventions: Drug: Eplerenone; Drug: placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; University of Pennsylvania
Not yet recruiting - verified August 2011 - Conditions: Metabolic Diseases; Diabetes Mellitus; Endocrine System Diseases; Glucose Metabolism Disorders
Interventions: Drug: Renin-Angiotensin-Aldosterone System (RAAS) Activation; Drug: Administration of Aliskiren, Spironolactone, or Placebo; Drug: Increased Dose, Combination, or Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified August 2011 - Condition: Premenstrual Dysphoric Disorder
Interventions: Drug: low dose oral contraceptive (20 ug ethinyl estradiol + 3 mg drospirenone); Drug: 20 ug ethinyl estradiol + 3 mg drospirenone; Drug: placebo
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill
Recruiting - verified May 2012 - Conditions: Type 2 Diabetes Mellitus; Vascular Disease
Interventions: Drug: Spironolactone; Drug: hydrochlorothiazide + potassium; Other: placebo
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Institutes of Health (NIH)
Recruiting - verified June 2011 - Conditions: Obesity; Hypertension
Interventions: Drug: eplerenone, amlodipine; Drug: eplerenone; Drug: eplerenone; Drug: amlodipine
Sponsors: University of Mississippi Medical Center; University of Mississippi Medical Center
Recruiting - verified April 2012 - Conditions: Polycystic Ovary Syndrome; Metabolic Syndrome
Interventions: Drug: Metformin; Drug: flutamide; Drug: drospirenone; Other: placebo
Sponsors: Northwestern University; Northwestern University; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2012 - Condition: Hypertension
Interventions: Drug: Clonidine; Drug: Nitroglycerin transdermal; Drug: Dipyridamole/ Aspirin (Aggrenox); Drug: Desmopressin (DDAVP); Drug: Sildenafil; Drug: Nifedipine; Drug: Hydralazine; Drug: Hydrochlorothiazide; Drug: Placebo; Drug: Bosentan; Drug: Diltiazem; Drug: Eplerenone; Drug: guanfacine; Dietary Supplement: L-arginine; Drug: captopril; Drug: carbidopa; Drug: losartan; Drug: metoprolol tartrate; Drug: nebivolol hydrochloride; Drug: prazosin hydrochloride; Drug: tamsulosin hydrochloride; Other: Head-up tilt.
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012
 |
Aldosterone Antagonists Clinical Trials |
